The intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine.HCl, may potentiate doxorubicin in the treatment of metastatic breast cancer: Results of a pilot study

This publication has 14 references indexed in Scilit:

• Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.
  Journal of Clinical Oncology, 1997
• Enhancement of tumor growth by drugs with some common molecular actions
  Molecular Carcinogenesis, 1996
• High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
  Journal of Clinical Oncology, 1995
• Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes
  European Journal Of Cancer, 1994
• Evidence for histamine uptake by murine hematopoietic progenitors
  Inflammation Research, 1994
• Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.
  Journal of Clinical Oncology, 1990
• Characterization of the Gastroprotective Effects of N, N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine Hydrochloride, a Non-H1/Non- H2 Histamine Antagonist
  Digestion, 1990
• Antiulcerogenic and antisecretory effects of a novel diphenylmethane derivative and antiestrogen binding site ligand
  Canadian Journal of Physiology and Pharmacology, 1988
• A diphenylmethane derivative specific for the antiestrogen binding site found in rat liver microsomes
  Biochemical and Biophysical Research Communications, 1984
• Osteoblastic response to successful treatment of metastatic cancer of the prostate
  American Journal of Roentgenology, 1979